What is Clomiphene?
Clomiphene citrate is a selective estrogen receptor modulator (SERM) that acts as the first-line oral medication for treating anovulatory infertility in women with polycystic ovary syndrome (PCOS), and it works by blocking estrogen receptors in the hypothalamus to trigger increased gonadotropin release and subsequent ovulation. 12
Mechanism of Action
Clomiphene competes with estrogen for estrogen-receptor-binding sites in the hypothalamus, pituitary, ovary, endometrium, vagina, and cervix 2. By blocking these receptors, it prevents negative feedback from circulating estrogen, which leads to:
- Increased release of pituitary gonadotropins (FSH and LH)
- Stimulation of folliculogenesis and steroidogenesis
- Growth of ovarian follicles with rising estradiol levels
- Eventually triggering a preovulatory gonadotropin surge and follicular rupture 2
The drug exhibits both estrogenic and antiestrogenic properties that vary by tissue type. Clomiphene exists as two isomers: zuclomiphene (cis) has greater estrogenic activity and a longer half-life (persisting for over a month), while enclomiphene (trans) is cleared more rapidly 23. Via estrogen receptor alpha (ERα), clomiphene acts as an agonist at low doses but becomes antagonistic at higher doses or when combined with higher estrogen concentrations. Via estrogen receptor beta (ERβ), it acts purely as an antagonist regardless of estrogen presence 3.
Primary Clinical Uses
Female Infertility (First-Line Indication)
Clomiphene citrate is recommended as first-line treatment for anovulatory infertility in women with PCOS 1. The Endocrine Society's 2013 clinical practice guideline establishes this as a strong recommendation, noting that estrogen modulators like clomiphene (and potentially letrozole) should be prioritized over insulin sensitizers like metformin 1.
Key efficacy data from clinical trials 2:
- Approximately 30% pregnancy rate in treated patients
- Multiple pregnancy rate of 7.98% (6.9% twins, 0.5% triplets, 0.3% quadruplets)
- Twin ratio of monozygotic to dizygotic approximately 1:5
- Overall infant survival from multiple pregnancies: 73%
Male Infertility (Off-Label Use)
Clomiphene has been used for 50 years in men with unexplained infertility, oligospermia, asthenospermia, hypogonadism, and nonobstructive azoospermia 4. Recent evidence shows:
- Mean total motile sperm count increased by 13.1 million after 12.9 months of treatment (p=0.005) 5
- Testosterone increased by 9.9 nmol/L, FSH by 4.9 IU/L, LH by 4.8 IU/L 5
- In obese men with androgen deficiency, clomiphene (12.5-50 mg daily) increased testosterone by 11.56 nmol/L 6
- Response is independent of age, BMI, baseline hormones, or treatment duration 5
For eugonadal men, clomiphene exhibits a ceiling effect: the testosterone-to-estradiol ratio only increases significantly when the baseline ratio is <200 7.
Dosing
Standard dosing for ovulation induction is not explicitly detailed in the FDA label, but clinical trials used clomiphene citrate at standard doses 2. For male infertility, doses range from 12.5-50 mg daily 56.
Side Effects and Safety Profile
Common Adverse Effects
- Hot flashes (most common across all SERMs) 8
- Multiple pregnancies (7.98% rate, predominantly twins) 2
Serious Risks
- Increased risk of thromboembolic events with continuous use 89
- Ovarian hyperstimulation syndrome (OHSS) - though metformin may be used as adjuvant therapy to prevent this in IVF cycles 1
Fetal Considerations
Congenital anomalies were reported at <1% rate for each specific abnormality type, with overall incidence within the range of the general population 2. The drug is readily absorbed orally and excreted principally in feces, with zuclomiphene persisting for over a month, meaning active drug may remain in the body during early pregnancy in women who conceive during treatment cycles 2.
Endometrial Effects
Unlike tamoxifen and toremifene (other SERMs), clomiphene's endometrial effects are less extensively documented in the provided evidence, though it does interact with estrogen receptors in the endometrium 2.
Important Clinical Considerations
Clomiphene has no progestational, androgenic, or antiandrogenic effects and does not interfere with pituitary-adrenal or pituitary-thyroid function 2. Some patients experience spontaneous ovulatory menses after discontinuing therapy, though there is no evidence of a true "carryover effect" 2.
For women with clomiphene-resistant PCOS, combining metformin with clomiphene leads to higher live birth rates than clomiphene alone (RR 6.4; 95% CI 1.2-35), and metformin alone shows higher live birth rates than laparoscopic ovarian drilling 1.